Dr Reddy's Proprietary Products Gain US Traction Amid Tough Q2
Executive Summary
Early traction for its differentiated neurology and dermatology formulations in the US and signs of ebbing volatility in emerging markets bode well for Dr Reddy's Laboratories, amid a sharp decline in second quarter profits on a year-on-year basis. Investors also have their eyes firmly set on progress of the firm's key generic opportunities for Copaxone, Aloxi and Gleevec in the US.
You may also be interested in...
Cipla 2.0: ‘Disproportionate’ US Growth, Getting The Profit Curve Right
Cipla is planning an ambitious growth trajectory, aiming to propel its US business “towards a $1bn generic enterprise” and develop a strong specialty franchise focused on its traditional stronghold, the respiratory segment, and the CNS space.
Cipla 2.0: ‘Disproportionate’ US Growth, Getting The Profit Curve Right
Cipla is planning an ambitious growth trajectory, aiming to propel its US business “towards a $1bn generic enterprise” and develop a strong specialty franchise focused on its traditional stronghold, the respiratory segment, and the CNS space.
Chinese Stamp On Indian Pharma; All Eyes On Regulatory Flow
The Fosun group led by its billionaire chair Guo Guangchang has snapped up the injectables firm Gland for around $1.26bn, the first mega Chinese buy in the Indian pharmaceutical space. The deal opens up many potential collaborative opportunities, though it remains to be seen how smoothly it sails through in the Indian regulatory maze.